Showing results (31-40 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Clinical Pharmacology|July 11, 2019
The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumoursFloor J E Lubberman, Winette T A van der Graaf, Lei Xu, et al.
British Journal of Clinical Pharmacology|December 2, 2025
Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistatAnnemieke M Peters van Ton, Nielka P van Erp, Annenienke C van de Ven, et al.
International Journal of Cancer|October 11, 2015
mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithmAnnelieke E C A B Willemsen, Jan C Grutters, Winald R Gerritsen, et al.
Cancer Chemotherapy and Pharmacology|September 14, 2019
A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokineticsFloor J E Lubberman, Guillemette E Benoist, Winald Gerritsen, et al.
British Journal of Clinical Pharmacology|September 8, 2017
Drug-drug interaction potential in men treated with enzalutamide: Mind the gapGuillemette Emma Benoist, Inge M van Oort, Stella Smeenk, et al.
Clinical Pharmacology and Therapeutics|June 1, 2025
Exploring the Association Between Intra-Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma PatientsAmy Rieborn, Eline L Giraud, Teun van Gelder, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2025
Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy-A case reportLotte M G Hulskotte, Loek A W de Jong, Alwin D R Huitema, et al.
British Journal of Clinical Pharmacology|August 26, 2021
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancerEmmy Boerrigter, Guillemette E Benoist, Joanneke K Overbeek, et al.
Therapeutic Advances in Medical Oncology|December 17, 2024
Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysisCatharina J P Op 't Hoog, Sabien J E Bosman, Emmy Boerrigter, et al.
Cancer Treatment Reviews|April 6, 2021
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic reviewSophie L Gerritse, Jorien B E Janssen, Mariette Labots, et al.
Pageof 13